Florida-based Relmada Therapeutics (Nasdaq: RLMD) posted another $21.8 million loss for the first three months of 2024, down both sequentially and year-over-year as the pre-revenue psychedelics firm continues its clinical trials with multiple drugs in development. The net loss is down from both the $25.2 million lost last quarter, as …
Curaleaf keeps its eyes on the prize: Europe
While the topic of potential rescheduling in the U.S. dominates so many cannabis earnings calls lately, Curaleaf Holdings (TSX: CURA) (OTCQX: CURLF) is staying focused on the up-and-coming European cannabis market. During the company’s call last week, Executive Chairman Boris Jordan and CEO Matt Darin highlighted the enthusiasm around demand …
New York OCM’s Alexander reportedly out, as regulators approve 104 adult-use licenses
The New York Cannabis Control Board seems to still be wading through the mud after announcing new winners in its adult-use lottery rollout, as challenges of enforcement and resource allocation loom. News also broke during the meeting that the state’s governor has asked the head of the the Office of …
DEA psychedelics ban hearing halted by lawsuit
A Drug Enforcement Administration judge has postponed a June hearing on the agency’s proposal to ban two psychedelic substances after a pharmaceutical company filed a federal lawsuit challenging the move, according to court documents released Thursday. Administrative Law Judge Paul Soeffing ordered the DEA to cancel the June 10 hearing …